Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tuxil is a brand of cough and cold remedies developed and manufactured by Fidson Healthcare Plc, a Nigerian pharmaceutical company. The product line includes multiple formulations designed for different symptomatic needs. **Tuxil-D** is a non-sedative daytime preparation containing cetirizine hydrochloride (an antihistamine), ammonium chloride (an expectorant), sodium citrate (a mucolytic and buffering agent), ephedrine hydrochloride (a decongestant), and menthol. **Tuxil-N** is a sedative nighttime formulation containing ephedrine, chlorphenamine (a sedating antihistamine), ammonium chloride, and sodium citrate. These products are marketed as branded generics for the treatment of cough, common cold, fever, allergies, and bronchial congestion. They work by loosening phlegm, clearing respiratory passages, and providing relief from allergic symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tuxil.